Trigeminal Neuralgia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, Mechanism Of Action, ROA, NDA, IND, And Companies

DelveInsight's, “Trigeminal Neuralgia Pipeline Insights 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Trigeminal Neuralgia pipeline landscape. It covers the Trigeminal Neuralgia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Trigeminal Neuralgia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Trigeminal Neuralgia Treatment Landscape @ Trigeminal Neuralgia Pipeline Outlook

Key Takeaways from the Trigeminal Neuralgia Pipeline Report

• On July 7, 2025, Noema Pharma AG revealed the initiation of a study focused on assessing the safety and efficacy of basimglurant (NOE-101) in individuals diagnosed with trigeminal neuralgia (TN). Basimglurant is a strong inhibitor of the metabotropic glutamate receptor 5 (mGluR5), a receptor involved in numerous functions across both the central and peripheral nervous systems. Blocking mGluR5 has demonstrated therapeutic promise in managing pain linked to disorders such as TN. Clinical findings have already indicated that the drug maintains a favorable safety profile in adults, adolescents, and children. This new trial is set to explore whether basimglurant can effectively reduce both the severity and duration of TN-related facial pain, with outcomes measured through patient pain diaries and the Patient-reported Global Impression of Change (PGI-C) in comparison with baseline assessments.
• DelveInsight's Trigeminal Neuralgia pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Trigeminal Neuralgia treatment.
• The leading Trigeminal Neuralgia Companies such as Biogen, Biohaven Pharmaceuticals, Noema Pharma AG, Pfizer and others.
• Promising Trigeminal Neuralgia Pipeline Therapies such as Carbon Dioxide Drug Delivery System (CDDS), Basimglurant, CNV1014802, Galcanezumab, COA566 and others.

Discover groundbreaking developments in Trigeminal Neuralgia Therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Trigeminal Neuralgia Clinical Trials Assessment

Trigeminal Neuralgia Emerging Drugs Profile

• Vixotrigine: Biogen

Vixotrigine (BIIB074) is a voltage and use-dependent sodium channel blocker. It is a centrally and peripherally acting small molecule. It is being developed by Biogen for the treatment of Trigeminal Neuralgia.

• Rimegepant: Biohaven Pharmaceuticals

Rimegepant is a Phase 2 calcitonin gene-related peptide receptor antagonists. It is being developed by Biohaven pharmaceuticals. The trail got initiated in June 2019 and is expected to get completed by October 2022 with expected 30 enrolled participants. (NCT03941834).

The Trigeminal Neuralgia Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Trigeminal Neuralgia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Trigeminal Neuralgia Treatment.
• Trigeminal Neuralgia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Trigeminal Neuralgia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Trigeminal Neuralgia market

Stay informed about the Trigeminal Neuralgia pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Trigeminal Neuralgia Unmet Needs

Trigeminal Neuralgia Companies

Biogen, Biohaven Pharmaceuticals, Noema Pharma AG, Pfizer and others.

Trigeminal Neuralgia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Trigeminal Neuralgia Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Transform your understanding of the Trigeminal Neuralgia Pipeline! See the latest progress in drug development and clinical research @ Trigeminal Neuralgia Market Drivers and Barriers, and Future Perspectives

Scope of the Trigeminal Neuralgia Pipeline Report

• Coverage- Global
• Trigeminal Neuralgia Companies- Biogen, Biohaven Pharmaceuticals, Noema Pharma AG, Pfizer and others.
• Trigeminal Neuralgia Pipeline Therapies- Carbon Dioxide Drug Delivery System (CDDS), Basimglurant, CNV1014802, Galcanezumab, COA566 and others.
• Trigeminal Neuralgia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Trigeminal Neuralgia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Rare Diseases Research–Access the Full Trigeminal Neuralgia Pipeline Analysis Today! @ Trigeminal Neuralgia Drugs and Companies

Table of Contents